TLR2 and non-small cell lung carcinoma: In a randomized controlled trial conducted by Belani et al., the efficacy and safety of the TLR2 agonist CADI-05 combined with cisplatin-paclitaxel as first-line therapy for advanced non-small cell lung cancer (NSCLC) were evaluated.